Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma

Asthma Clinical Trial

Official title:

Multicenter Randomised Controlled Trial of Episodic Fluticasone Versus Placebo in Viral-induced Asthma in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00238927
• Other study ID #: FAP30006
• Secondary ID: MRC/PMAC program
• Status: Completed
• Phase: Phase 4
• First received: October 12, 2005
• Last updated: March 25, 2014
• Start date: November 1999
• Est. completion date: September 2005

Study information

• Verified date: March 2014
• Source: McGill University Health Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine, in children aged 1 to 6 years with recurrent asthma induced by upper respiratory tract infections (URTI), whether the administration of high doses of inhaled fluticasone started at the onset of symptoms of a cold will result in a reduced severity and shorter duration of asthma exacerbations and will not be associated with reduced growth velocity, osteopenia, and adrenal suppression.

Description:

Preschool-aged children, who represent over half of asthmatics presenting to a pediatric emergency department with acute asthma, also account for most hospital admissions for pediatric asthma. More than 80% of exacerbations of preschool-aged children are triggered by upper respiratory tract infections (URTIs). Current management of this condition is clearly unsatisfactory. In most cases, there is a 24-48 hour delay between the first signs of a viral infection and the onset of asthmatic symptoms, suggesting that a window of opportunity where an intervention could be initiated to alter the severity of the asthma exacerbation. Prior trials testing chronic inhaled steroids throughout the viral season failed to demonstrate any benefit while those examining episodic inhaled steroids at onset of URTI reported a modest benefit on duration and severity of symptoms. The selection of children with mild exacerbations, the small sample size, the cross-over design, the short study period, and the relatively low doses of inhaled steroids may have limited the magnitude of observed benefits attributable to episodic treatment.

The aim of this multicentre double-blind parallel-group placebo-controlled randomized trial is to compare the effectiveness of high doses (750 ug bid) of inhaled fluticasone with HFA propellant versus placebo started at the onset of a viral illness in attenuating the severity and duration of URTI-induced asthma in young children during a 12-month study period. Children aged 1 to 6 years with at least 2 URTI-induced asthma of moderate severity, i.e. requiring a short course of systemic steroids, in the previous 12 months or 1 in the previous 6 months, and no inter-current symptoms will be selected for inclusion. Fluticasone 250 ug or placebo will be administered at a dose of 3 puffs BID from the onset of viral illness until 48 hours without asthma symptoms for a maximum of 10 days. This dose was chosen to approach the efficacy of systemic steroids with significantly less adverse effects. Inhaled salbutamol will be administered as bronchodilator on an "as needed" basis for relief of asthma symptoms at a dose of 2 to 4 puffs of 100 ug at 4-hour interval or longer. A 7-day run-in period will serve to (1) establish the absence of chronic symptoms and the infrequent use of salbutamol and (2) obtain confirmation of eligibility by the pharmacy reports of all corticosteroid preparation dispensed in the preceding 12 months. Eligible children will receive baseline measurement of IgE as measure of atopy, varicella antibodies and of the safety parameters, including height, basal cortisol, and lumbar bone density. Children will then be randomly allocated to one of the two treatments in blocks of 4 with stratification on type of spacer (with mask or with mouthpiece) and recruitment site. Children will be followed every 3±1/2 months by the site investigators or delegates until the end of the 12-month study period. The primary endpoint is the proportion of URTIs in each group requiring treatment with systemic corticosteroids as confirmed by review of medical records and pharmacy records of prescriptions dispensed. Secondary endpoints include other measures of the severity and duration of exacerbations, adjusted for the number of URTIs experienced by each child during the study period. Compliance with the study drug and the use of salbutamol (an important measure of severity) will be documented by the Doser, a device attached to the study inhalers which records, in a blinded mode, the date and number of doses administered over a 45-day period. The safety profile will be examined with the growth velocity, the basal cortisol, and the change in lumbar bone density between baseline and the end of the study period.

A clinically important reduction in the severity and duration of viral-induced asthma will lead to other trials to establish the lowest effective dose of fluticasone. If no adverse effects on growth, bone density, and adrenal function are detected with the tested dose, safety may be assumed at lower doses. An absence of benefit will lead to the abandonment of this frequently used treatment strategy to consider alternative therapies for young children with URTI-induced asthma, who contribute to a marked proportion of health care spending.

An upper respiratory tract infection is defined as rhinorrhea, nasal congestion, sore throat, ear ache, with or without fever, lasting >=48 hours.

URTI-induced asthma is defined by wheezing in association with an URTI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: September 2005
• Est. primary completion date: September 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 6 Years

Eligibility

Inclusion Criteria:

• (1) Children aged 1-6 years,

• (2) they had at least 2 documented episodes of URTI-induced asthma requiring systemic (i.e., oral, intravenous, or intramuscular) corticosteroids in the previous 12 months or 1 episode in the previous 6 months,

• (3) no intercurrent symptoms (i.e., cough, wheezing, or observed dyspnea) documented for at least 7 days between wheezing episodes,

• (4) no suspicion of allergy to pollen or perennial allergens, and

• (5) caregivers have a good understanding of French or English

Exclusion Criteria:

• (a) other chronic diseases such as cystic fibrosis, bronchopulmonary dysplasia, cardiac disease, kidney disease, gastro-oesophageal reflux requiring treatment,

• (b) intake, in the 21 days preceding randomization, of inhaled, nasal, or oral corticosteroids, leukotriene antagonists, cromolyn, nedocromyl, or ketotifen, -(c) prior intubation for an asthma exacerbation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)

Locations

Country	Name	City	State
Canada	Hopital Maisonneuve-Rosemont	Montreal	Quebec
Canada	Hopital Sainte-Justine	Montreal	Quebec
Canada	Montreal Children's Hospital	Montreal	Quebec
Canada	Centre Pédiatrique La Courte Échelle	Repentigny	Quebec
Canada	Centre Hospitalier Universitaire de Sherbrooke	Sherbrooke	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
McGill University Health Center	Medical Research Council of Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of upper respiratory tract infections (URTIs) in each group requiring treatment with systemic corticosteroids as confirmed by review of medical records and pharmacy records of prescriptions dispensed.
Secondary	Rate of unscheduled visits for asthma to an acute care setting adjusted for the number of upper respiratory tract infections (URTIs).
Secondary	Rate of hospital admissions for asthma adjusted for the number of URTIs.
Secondary	Maximum and mean number of puffs of ß2-agonists/day during URTI illness.
Secondary	Peak and mean symptom scores during URTI illness
Secondary	The mean # of days/URTI during which rescue ß2-agonists were used for asthma symptoms.
Secondary	The mean # of days/URTI during which asthma symptoms were observed
Secondary	growth velocity from baseline to endpoint
Secondary	change in bone mineral density between baseline and endpoint
Secondary	proportion of osteopenia at endpoint
Secondary	change from baseline in hypothalamo-pituitary adrenal function (basal cortisol) at endpoint
Secondary	proportion of adrenal suppression at endpoint
Secondary	proportion of treatment interruption due to perceived ineffectiveness in each group